AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
